



FINANCIAL TEAR SHEET

Corporate Profile

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Sanfilippo disorder, Batten disease, Fanconi anemia and other rare disorders.

Primary IR Contact

Andre'a Lucca
 Director of Communications
 PlasmaTech
 Biopharmaceuticals, Inc.
Phone: 212-786-6208
E-mail:
 alucca@plasmatechbio.com

Stock Performance

ABEO (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$16.05
Change (%)	0.00 (0.00%)
Volume	0
52 Week Low	\$4.55
Market Cap	\$759,249,824
Rolling EPS	-0.70
PE Ratio	0
Shares Outstanding	47,305,285



Data as of May 23, 2018 4:00 p.m. ET

Recent Press Releases & Upcoming Events

May 18, 2018
Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting

There are currently no events scheduled.

May 17, 2018
Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting

May 14, 2018
Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors

SEC Filings

Filing Date	Form
May 23, 2018	4
May 23, 2018	4
May 21, 2018	3
May 21, 2018	3

Corporate Governance

Data provided by Nasdaq. Minimum 15 minutes delayed.